Charles Schwab Investment Management Inc. Cuts Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Charles Schwab Investment Management Inc. cut its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 29.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,224,727 shares of the biopharmaceutical company’s stock after selling 941,519 shares during the period. Charles Schwab Investment Management Inc. owned 4.11% of Emergent BioSolutions worth $18,576,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EBS. Tidal Investments LLC bought a new stake in shares of Emergent BioSolutions in the first quarter worth about $34,000. CWM LLC increased its stake in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Emergent BioSolutions during the 2nd quarter worth approximately $41,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares in the last quarter. Finally, Verus Capital Partners LLC bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at approximately $68,000. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Stock Down 1.5 %

NYSE EBS opened at $9.01 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The firm has a market capitalization of $488.16 million, a price-to-earnings ratio of -2.20 and a beta of 1.59. The company has a fifty day moving average of $9.38 and a two-hundred day moving average of $8.54.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on EBS shares. Benchmark boosted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.